# US 8,541,464 B2 · Treatment of atrial fibrillation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,464 B2
- Document ID: US8541464B2
- Status: Granted
- Kind: B2
- Application number: 13/509,752
- Filed: 2010-11-16
- Published: 2012-12-06
- Granted: 2013-09-24
- Earliest claimed: 2009-11-17
- Assignees: HUYA Biosciences International LLC
- Applicants: Gary T. Elliott
- Inventors: Gary T. Elliott
- Web page: https://patentgrep.com/patent/US8541464B2

## CPC

- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 μM to about 20 μM.

## Claims

### Claim 1

A method of treating atrial fibrillation (AF), comprising administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof, such that the maximum steady state plasma concentration (Cmax) of said active agent in said subject is in the range from about 1 μM to about 20 μM.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said Cmax is in the range from about 2 μM to about 10 μM.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the amount of said active agent is in the range from about 3 mg/kg to about 30 mg/kg.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the amount of said active agent is in the range from about 5 mg/kg to about 10 mg/kg.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said composition further comprises a pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said pharmaceutically acceptable excipient is selected from the group consisting of a buffer, a diluent, a stabilizer and combinations thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said administering is by means of intramuscular injection, intravenous injection, subcutaneous injection, or oral, transdermal, inhalation, rectal, sublingual, buccal, intravaginal or nasal administration.

### Claim 9 (depends on 2)

The method according claim 2, wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.

### Claim 10 (depends on 3)

The method according claim 3, wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.

### Claim 11 (depends on 4)

The method according claim 4, wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.

### Claim 12 (depends on 2)

The method according to claim 2, wherein said composition further comprises a pharmaceutically acceptable excipient.

### Claim 13 (depends on 3)

The method according to claim 3, wherein said composition further comprises a pharmaceutically acceptable excipient.

### Claim 14 (depends on 4)

The method according to claim 4, wherein said composition further comprises a pharmaceutically acceptable excipient.